At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
SAN-300 0.5 mg/kg QW +5 moredrug
Likely dose
SAN-300 0.5 mg/kg QWfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
In Brief
A Phase 2 clinical trial evaluating SAN-300 0.5 mg/kg QW, SAN-300 1.0 mg/kg QW, and 4 other interventions for Rheumatoid Arthritis. Completed, enrolled 41 participants across 12 sites.
Detailed Summary
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedJan 2014
Primary CompletionFeb 2017
Study CompletionMar 2017
TodayJul 2026
First PostedJan 28, 2014
Enrollment StartDec 1, 2013
Primary CompletionFeb 23, 2017
Study CompletionMar 23, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.4 years ago
Interventions
SAN-300 0.5 mg/kg QWdrug
SAN-300 1.0 mg/kg QWdrug
SAN-300 2.0 mg/kg QOWdrug
SAN-300 4.0 mg/kg QOWdrug
SAN-300 4.0 mg/kg QWdrug
Placebodrug